Sugammadex
DrugAt the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
Other names: bridion
NCT Number: NCT05313100
We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 4
40 patients from American Society of Anesthesiologist (ASA) I- II class, being smokers for at least 10 years or non-smokers, who will undergo elective surgery were included in this randomized prospective study. Patients underwent routine monitoring and neuromuscular monitoring. Propofol 2 mg/kg and intravenous fentanyl 1 mcg/kg were applied at induction. After the loss of eyelash reflex, intravenous rocuronium 0,6 mg/kg was administered. The patient was intubated at a Train of Four count of 2. Anesthesia was continued with 50% O2 + 50% air and sevoflurane 2 % . Rocuronium 0,15 mg/kg was administered when TOF (Train of Four) counter reached 2 during the operation. Sugammadex 2 mg/kg was administered at the end of the operation. The time to reach Train of Four values of 0,7-0,8-0,9 were recorded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
Other names: bridion
Time frame: six months
Time to reach TOF %90 measurement after given neuromuscular blocker reverse agent
Duzce University
Other
The Evaluation of the Effects of the Use of Rocuronium and Sugammadex on Neuromuscular Block in Smoker
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06220136
Anesthesia, General, Neuromuscular Blockade
Ankara, Altındağ, Turkey (Türkiye)
View Trial DetailsNCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT05006807
Neuromuscular Blockade
Seattle, Washington, United States
View Trial DetailsNCT07404579
Neuromuscular Blockade
Zhengzhou, Henan, China
View Trial Details